Fulcrum Therapeutics Inc (FULC)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

26 LANDSDOWNE STREET CAMBRIDGE, MA 02139

Fulcrum Therapeutics, Inc. produces and distributes pharmaceutical products. The Company develops and produces drugs for transforming gene regulation in diseases. Fulcrum Therapeutics serves the healthcare sectors in the State of Massachusetts.

Data as of 2020-05-24
Market Cap430.301 Million Shares Outstanding23.373 Million Avg 30-day Volume66.676 Thousand
P/E Ratio Dividend Yield EPS-0.29
Price/Sales573.734 Price cash flow ratio Price free cash flow ratio-9.4
Book Value3.02 Price to Tangible Book6.09 Alpha
Short Interest Ratio % Short Interest to Float R-squared
BETA 52-week High/Low22.96 / 4.37 Stddev
View SEC Filings from FULC instead.

View recent insider trading info

Funds Holding FULC (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding FULC BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

11.9 Thousand total shares from 3 transactions

Exercise Derivative Conversion (M)

1.9 Thousand total shares from 1 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

GOULD ROBERT J SEE REMARKS

  • Officer
  • Director
552,345 2020-05-26 5

CASDIN PARTNERS MASTER FUND, L.P.

CASDIN CAPITAL, LLC

CASDIN PARTNERS GP, LLC

CASDIN ELI

  • 10% Owner
4,849,524 2020-05-22 0

GLAXOSMITHKLINE PLC

  • Director
2,253,660 2020-05-21 2

GERAGHTY JAMES A

  • Director
0 2020-05-12 2

CADAVID DIEGO SVP CLINICAL DEVELOPMENT

  • Officer
66,785 2020-05-12 6

THOMSON PETER G. VP FINANCE & ACCOUNTING

  • Officer
21,071 2020-05-11 5

SANOFI

23,221,451 2020-03-09 2

HAVILAND KATE CHIEF OPERATING OFFICER

  • Officer
42,838 2020-03-09 2

WALLACE OWEN B. CHIEF SCIENTIFIC OFFICER

  • Officer
127,088 2020-02-19 4

THIRD ROCK VENTURES IV, L.P.

THIRD ROCK VENTURES GP IV, L.P.

TRV GP IV, LLC

  • 10% Owner
1,419,900 2020-02-18 2

STUART BRYAN CHIEF OPERATING OFFICER

  • Officer
0 2020-01-23 3

DORTON KATINA

  • Director
0 2020-01-02 2

THIRD ROCK VENTURES III, L.P.

THIRD ROCK VENTURES GP III, L.P.

TRV GP III, LLC

STARR KEVIN P

TEPPER ROBERT I

  • 10% Owner
5,962,202 2019-07-22 2

6 DIMENSIONS CAPITAL, L.P.

  • 10% Owner
559,821 2019-07-22 2

SECTION 32 FUND 2, LP

SECTION 32 GP 2, LLC

MARIS WILLIAM J

  • 10% Owner
464,285 2019-07-22 2

LEVIN MARK J

  • Director
  • 10% Owner
5,962,202 2019-07-22 2

COLLINS JAMES J.

  • Director
0 2019-07-18 2

EZEKOWITZ ALAN

  • Director
0 2019-07-18 2

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

GOULD ROBERT J - Director - Officer SEE REMARKS

2020-05-26 S 2,500 $20.00 d 552,345 552,345.00 direct yes

CADAVID DIEGO - Officer SVP CLINICAL DEVELOPMENT

2020-05-12 S 1,860 $18.00 d 66,785 66,785.00 direct yes

CADAVID DIEGO - Officer SVP CLINICAL DEVELOPMENT

2020-05-12 M 1,860 $4.83 a 68,645 66,785.00 direct yes

CADAVID DIEGO - Officer SVP CLINICAL DEVELOPMENT

2020-05-12 M 1,860 d 15,997 66,785.00 direct yes

THOMSON PETER G. - Officer VP FINANCE & ACCOUNTING

2020-05-11 S 7,500 $16.00 d 21,071 21,071.00 direct yes

Elevate your investments